StemCell Therapy

Centenarian Daphne Brann, 110, exercising her right to vote!

The Genetics of Longevity Study

The Genetics of Longevity Study is an international survey of centenarians and their siblings. We examine potential genes they may have in common and other lifestyle factors that could influence the ability to achieve extreme old age. Participation involves health and family history questionnaires, as well as a small blood donation for the genetic aspect of the study. To enter the study we ask that the subject be 105+ years old. If the potential subject has living siblings, then a younger centenarian may be eligible.

Betty Colleran, 70, and mother Elizabeth Stanton, 100, together looking at family photographs.

The Genetics of Longevity Study: Offspring Study

The Genetics of Longevity Study: Offspring Study looks at children of centenarians and their spouses. We believe they may be a valuable group to study for genetic and environmental factors contributing to the ability to live to very old age in good health. We also enroll childrens spouses as a control group.

Dirk Struik, a leader in ethnomathematics, at his home at age 104.

The Genetics of Longevity Study: Neuropsychological Study

The Genetics of Longevity Study: Neuropsychological Study assesses cognitive function because we believe Alzheimers Disease is either markedly delayed, or even absent in some subjects. Approximately 30% of our subjects consent to donate their brains for detailed study after they have passed away.

If you or a family member(s) could be eligible to participate in one of our studies, please contact us.

Here is the original post:
Studies New England Centenarian Study BUMC

By: Ian Murnaghan BSc (hons), MSc - Updated: 13 Aug 2018| *Discuss

Stem cells have an interesting history that has been somewhat tainted with debate and controversy. In the mid 1800s it was discovered that cells were basically the building blocks of life and that some cells had the ability to produce other cells.

Attempts were made to fertilise mammalian eggs outside of the human body and in the early 1900s, it was discovered that some cells had the ability to generate blood cells.

In 1968, the first bone marrow transplant was performed to successfully treat two siblings with severe combined immunodeficiency. Other key events in stem cell research include:

More recently, in 2005, scientists at Kingston University in England were purported to have found another category of stem cells. These were named cord blood embryonic-like stem cells, which originate in umbilical cord blood. It is suggested that these stem cells have the ability to differentiate into more cell types than adult stem cells, opening up greater possibilities for cell-based therapies. Then, in early 2007, researchers led by Dr. Anthony Atala claimed that a new type of stem cell had been isolated in amniotic fluid. This finding is particularly important because these stem cells could prove to be a viable alternative to the controversial use of embryonic stem cells.

Over the last few years, national policies and debate amongst the public as well as religious groups, government officials and scientists have led to various laws and procedures regarding stem cell harvesting, development and treatment for research or disease purposes. The goals of such policies are to safeguard the public from unethical stem cell research and use while still supporting new advancements in the field.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

khedr - 10-Jul-18 @ 10:10 AM

Prof - 11-Jun-18 @ 10:51 PM

BOOMBOXPARADE - 3-May-18 @ 1:55 PM

ash - 20-Apr-18 @ 10:33 PM

autismsms - 9-Mar-18 @ 3:23 AM

Vicky - 23-Apr-17 @ 6:33 PM

Matapurkar - 6-Dec-16 @ 3:12 PM

Ben - 29-Oct-16 @ 5:23 PM

Jobbo - 5-Aug-16 @ 12:50 AM

Student101 - 10-Apr-16 @ 9:07 PM

StemCellProjectWrite - 14-Jan-16 @ 7:31 PM

Jojo - 13-Nov-15 @ 7:33 AM

Chloe - 12-Nov-15 @ 5:03 AM

ugdekichaman - 11-Nov-15 @ 1:02 PM

Cells - 2-Nov-15 @ 3:40 AM

Jim - 6-Jul-15 @ 10:02 PM

Ramen Sarkar - 23-Jun-15 @ 9:46 AM

Ramen Sarkar - 18-Jun-15 @ 7:26 PM

tera baap - 17-May-15 @ 9:46 AM

almighty.king.jay - 25-Mar-15 @ 4:18 PM

Bobby - 1-Dec-14 @ 4:23 PM

Adil Ahmed 255 - 20-Nov-14 @ 10:48 AM

ExploreStemCells - 22-Oct-14 @ 2:18 PM

Yusuf Syed - 22-Oct-14 @ 1:30 PM

amaad - 22-Oct-14 @ 1:27 PM

dgdsfbgf - 22-Sep-14 @ 3:18 PM

coline - 9-Aug-14 @ 2:13 PM

Manoj Jain - 6-Jul-14 @ 9:35 AM

sri - 19-Mar-14 @ 7:13 PM

jimmy - 25-Feb-14 @ 3:19 PM

Title:

(never shown)

See the rest here:
History of Stem Cell Research

Wikimedia list article

This is a list of British monarchs by longevity since the Union of the Crowns of England, Scotland and Ireland in 1603. To maintain consistency within the table, the dates of birth and death for each monarch are given in New Style. Two measures of the longevity are giventhis is to allow for the differing number of leap days occurring within the life of each monarch. The first column is the number of days between date of birth and date of death, allowing for leap days; the second column breaks this number down into years, and days, with the years being the number of whole years the monarch lived, and then days after his or her last birthday. Elizabeth II (queen since 6 February 1952), is the longest lived British sovereign.

*Updated daily according to UTC. While Queen Victoria lived for only 4 days more than George III in terms of years and days format, she actually lived for five days more because there were 20 leap days during Victoria's life and only 19 leap days during the life of George III.

If Charles, Prince of Wales, were to accede to the throne, he would immediately be ranked 8th with an age of 70years, 119days. If instead his son, William, Duke of Cambridge, were to accede any time before September 2030, he would be ranked 18th.

Read this article:
List of British monarchs by longevity - Wikipedia

Overview

Diabetes mellitus refers to a group of diseases that affect how your body uses blood sugar (glucose). Glucose is vital to your health because it's an important source of energy for the cells that make up your muscles and tissues. It's also your brain's main source of fuel.

The underlying cause of diabetes varies by type. But, no matter what type of diabetes you have, it can lead to excess sugar in your blood. Too much sugar in your blood can lead to serious health problems.

Chronic diabetes conditions include type 1 diabetes and type 2 diabetes. Potentially reversible diabetes conditions include prediabetes when your blood sugar levels are higher than normal, but not high enough to be classified as diabetes and gestational diabetes, which occurs during pregnancy but may resolve after the baby is delivered.

Diabetes symptoms vary depending on how much your blood sugar is elevated. Some people, especially those with prediabetes or type 2 diabetes, may not experience symptoms initially. In type 1 diabetes, symptoms tend to come on quickly and be more severe.

Some of the signs and symptoms of type 1 and type 2 diabetes are:

Type 1 diabetes can develop at any age, though it often appears during childhood or adolescence. Type 2 diabetes, the more common type, can develop at any age, though it's more common in people older than 40.

To understand diabetes, first you must understand how glucose is normally processed in the body.

Insulin is a hormone that comes from a gland situated behind and below the stomach (pancreas).

Glucose a sugar is a source of energy for the cells that make up muscles and other tissues.

The exact cause of type 1 diabetes is unknown. What is known is that your immune system which normally fights harmful bacteria or viruses attacks and destroys your insulin-producing cells in the pancreas. This leaves you with little or no insulin. Instead of being transported into your cells, sugar builds up in your bloodstream.

Type 1 is thought to be caused by a combination of genetic susceptibility and environmental factors, though exactly what those factors are is still unclear. Weight is not believed to be a factor in type 1 diabetes.

In prediabetes which can lead to type 2 diabetes and in type 2 diabetes, your cells become resistant to the action of insulin, and your pancreas is unable to make enough insulin to overcome this resistance. Instead of moving into your cells where it's needed for energy, sugar builds up in your bloodstream.

Exactly why this happens is uncertain, although it's believed that genetic and environmental factors play a role in the development of type 2 diabetes too. Being overweight is strongly linked to the development of type 2 diabetes, but not everyone with type 2 is overweight.

During pregnancy, the placenta produces hormones to sustain your pregnancy. These hormones make your cells more resistant to insulin.

Normally, your pancreas responds by producing enough extra insulin to overcome this resistance. But sometimes your pancreas can't keep up. When this happens, too little glucose gets into your cells and too much stays in your blood, resulting in gestational diabetes.

Risk factors for diabetes depend on the type of diabetes.

Although the exact cause of type 1 diabetes is unknown, factors that may signal an increased risk include:

Researchers don't fully understand why some people develop prediabetes and type 2 diabetes and others don't. It's clear that certain factors increase the risk, however, including:

Any pregnant woman can develop gestational diabetes, but some women are at greater risk than are others. Risk factors for gestational diabetes include:

Long-term complications of diabetes develop gradually. The longer you have diabetes and the less controlled your blood sugar the higher the risk of complications. Eventually, diabetes complications may be disabling or even life-threatening. Possible complications include:

Nerve damage (neuropathy). Excess sugar can injure the walls of the tiny blood vessels (capillaries) that nourish your nerves, especially in your legs. This can cause tingling, numbness, burning or pain that usually begins at the tips of the toes or fingers and gradually spreads upward.

Left untreated, you could lose all sense of feeling in the affected limbs. Damage to the nerves related to digestion can cause problems with nausea, vomiting, diarrhea or constipation. For men, it may lead to erectile dysfunction.

Most women who have gestational diabetes deliver healthy babies. However, untreated or uncontrolled blood sugar levels can cause problems for you and your baby.

Complications in your baby can occur as a result of gestational diabetes, including:

Complications in the mother also can occur as a result of gestational diabetes, including:

Prediabetes may develop into type 2 diabetes.

Type 1 diabetes can't be prevented. However, the same healthy lifestyle choices that help treat prediabetes, type 2 diabetes and gestational diabetes can also help prevent them:

Lose excess pounds. If you're overweight, losing even 7 percent of your body weight for example, 14 pounds (6.4 kilograms) if you weigh 200 pounds (90.7 kilograms) can reduce the risk of diabetes.

Don't try to lose weight during pregnancy, however. Talk to your doctor about how much weight is healthy for you to gain during pregnancy.

To keep your weight in a healthy range, focus on permanent changes to your eating and exercise habits. Motivate yourself by remembering the benefits of losing weight, such as a healthier heart, more energy and improved self-esteem.

Sometimes medication is an option as well. Oral diabetes drugs such as metformin (Glucophage, Glumetza, others) may reduce the risk of type 2 diabetes but healthy lifestyle choices remain essential. Have your blood sugar checked at least once a year to check that you haven't developed type 2 diabetes.

Aug. 08, 2018

View post:
Diabetes - Symptoms and causes - Mayo Clinic

");}

Genetics is the study of genes and heredity. It studies how living organisms, including people, inherit traits from their parents. Genetics is generally considered part of the science of biology. Scientists who study genetics are called geneticists.

What are genes?

Genes are the basic units of heredity. They consist of DNA and are part of a larger structure called the chromosome. Genes carry information that determine what characteristics are inherited from an organism's parents. They determine traits such as the color of your hair, how tall you are, and the color of your eyes.

What are chromosomes?

Chromosomes are tiny structures inside cells made from DNA and protein. The information inside chromosomes acts like a recipe that tells cells how to function. Humans have 23 pairs of chromosomes for a total of 46 chromosomes in each cell. Other plants and animals have different numbers of chromosomes. For example, a garden pea has 14 chromosomes and an elephant has 56.

What is DNA?

The actual instructions inside the chromosome is stored in a long molecule called DNA. DNA stands for deoxyribonucleic acid.

Gregor Mendel is considered the father of the science of genetics. Mendel was a scientist during the 1800s who studied inheritance by experimenting with pea plants in his garden. Through his experiments he was able to show patterns of inheritance and prove that traits were inherited from the parents.

See original here:
Biology for Kids: Genetics - ducksters.com

This information is intended for general information only and should not be considered as medical advice on the part of Health-Tourism.com. Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

What is a PET scan? A PET scan (positron emission tomography) is an imaging test that can help reveal how your tissues and organs are functioning. To show this chemical activity, a small amount of radioactive material must enter your body.

The precise type of radioactive material, and its delivery method, depends on which organ or tissue is being studied by the PET scan. The radioactive material may be injected into a vein, inhaled or swallowed.

What are PET scans used for? Currently, PET scans are most commonly used to detect:- cancer-heart problems- brain disorders- central nervous system disorders

Is the PET scan painfull? When the radioactive substance is inserted into your vein you will feel temporary pain. There shouldn't be any pain during the actual PET scan.What other tests are combined with a PET scan? PET scan is often combined with other imaging tests, such as CT scan and MRI. The combination of the testsimproves the clarity of the images and makes it easier for the physician to interpret the results.

Duration of procedure/surgery : The test takes between 1.5 to 2 hours to complete.

Days admitted : PET scan is done on an outpatient basis. No hospitalization is required.

Risks : A radioactive substance is used during a PET scan, but the amount of radiation that you are exposed to is low and is not considered dangerous. However, for pregnant woman and for woman who are breastfeeding, the radioactive material might be harmful.

Here is the original post:
PET Scan in Costa Rica - Health-Tourism.com

Integrative Medical Approach

Integrative medicine places the patient at the center of a holistic approach to medical care. Patient's individual needs, risks, and goals are the main driving forces of any integrative therapy. Physicians practicing integrative medicine emphasize that treatment of every aspect of a person's health is crucial to the success of the healing process:

To request more information, please contact our Coopersville integrative medicine clinic today! Call (616) 426-6163 or contact Elite Health online.

Integrative medicine is a multi-disciplinary approach that combines the scientific advances and a variety of effective therapies to treat disease.

Integrative medicine combines conventional and complementary treatment options to achieve optimal health for the patient. It is based on the research which demonstrates that the human body has an innate healing mechanism. Illness occurs when the regenerative processes in the body are disturbed, and the body can no longer keep itself healthy.

Integrative medicine emphasizes the use of the least invasive treatment options necessary to bring the body to a healthy state.

Integrative medicine physicians focus on health optimization and often combine a variety of methods to optimize their patients' health:

To request more information, please contact our Coopersville integrative medicine clinic today! Call (616) 426-6163 or contact Elite Health online.

Here is the original post:
Integrative Medicine Clinic in Coopersville, MI

If you believe that prevention is the best cure, then youve come to the right place. Welcome to Personalized Wellness Internal Medicine.

Even prior to the opening of our new state-ofthe-art Hoffman Estates office in 2013, we have been dedicated to a patient-centered approach to medical care. By combining the best of traditional Internal medicine and complementary integrative medicine, Dr. Mary George helps her patients transition from disease care to optimal health and wellness true healthcare. With the affiliation with MDVIP (as of August 2018), a national leader in wellness and prevention, this vision has become a true reality.

With a strong focus on preventive care and wellness, Personalized Wellness Internal Medicine offers unique treatment options for unique health challenges in people of all ages. Dr. George offers personal, one-on-one care with a bedside manner that makes patients feel welcome and comfortable. She gives you the time you need to express any health concerns. She attentively listens and takes as much time as necessary to provide thorough consultation, diagnosis, and treatment. Dr. George will take the time to answer all your questions. Educating and empowering the patient allows each individual to pursue, achieve and maintain optimal health and wellness.

Read more:
Personalized Wellness | Internal Medicine

Bioinformatics implies a multidisciplinary field that seeks to analyze and manage vast quantities of biological, molecular and genetic data through computer technology. Personalized Medicine is an emerging field that uses an individuals genetic profile to aid in the diagnosis, prevention, and treatment of diseases.

Created in 2015 and led by Dr. Kathleen Barnes, the Colorado Center for Personalized Medicines (CCPM) mission is to integrate bioinformatics and personalized medicine using patient health record information and big data with genetic information to develop personally tailored treatments and cures for different illnesses and diseases. This will be done by combining cutting edge biomedical technology with large-scale computing and the latest in genetic sequencing technology.

Kathleen Barnes: This Is What People Are Talking About When They Say Big Data.

Discoveries like these have the potential to improve treatment for complex diseases, as well as to help identify and screen high-risk populations. But personalized medicine also aims higher, at understanding how and why genes cause disease and why, sometimes, they don't.

Read the original:
Division of Biomedical Informatics and Personalized ...

By: Ian Murnaghan BSc (hons), MSc - Updated: 18 Dec 2018| *Discuss

Although many people may think of a transplant to mean replacing a diseased organ with another one, such as in heart or liver transplants, stem cells have an important and often life saving use for treating disease.

A stem cell transplant doesn't involve surgery in the same sense as an organ transplant and the procedure is simplistic in comparison. Its benefit, however, can be just as enormous.

In most cases, the benefits of stem cell transplants will likely outweigh the risk of complications and these techniques can truly be life-saving for conditions such as leukaemia and aplastic anaemia. It is hoped and anticipated that future research can yield successful therapies for a broader range of diseases.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

LauraN - 19-Feb-18 @ 11:47 AM

Ted - 18-Feb-18 @ 7:20 PM

Rnbarb - 26-Sep-17 @ 2:48 AM

NONE - 7-Sep-16 @ 9:30 PM

Glasdegib - 13-Aug-15 @ 9:23 AM

Kris - 14-Nov-14 @ 1:44 PM

Krupa - 24-Sep-14 @ 8:18 AM

kylie - 18-May-14 @ 8:12 PM

Title:

(never shown)

More here:
Why Perform a Stem Cell Transplant?

Stem cells are powerful, adaptable cells that can be used to promote healing and reverse damage. Stem cells are found in various places within the human body, but the purest stem cells are found in the umbilical cord.

Stem cells can be used in treatments for many different types of diseases. One of the main places young stem cells are found is in cord blood, which can be stored at birth and saved for future use if needed. Stem cells are also found in other places in the human body, including blood and bone marrow.

Regenerative transplants use stem cells from three main sources:

Bone marrow is tissue located in the center of your bones, making healthy blood cells that strengthen your immune system and fight off outside infections. A large amount of cells are located in bone marrow, and doctors frequently use hip bone marrow for most transplants, since the stem cells in this area are the most plentiful.

When doctors remove bone marrow, the patient receives anesthesia. This puts them to sleep and numbs any pain from the surgery. Doctors then insert a large needle, and pull the liquid marrow out. Once enough bone marrow is harvested, the solution is filtered and cryogenically frozen.

When a patient needs bone marrow for a transplant, stem cells are thawed and injected into the bloodstream. The cells then make their way to the bone marrow, and start producing new blood cells this process usually takes a few weeks.

While most people have a small amount of stem cells in their bloodstream, donors produce more stem cells after taking growth factor hormones. Doctors give these medications a few days before stem cell harvesting, which makes the bone marrow push more cells into the bloodstream.

During the harvesting procedure, doctors use a catheter to draw out blood. The blood moves through a machine, which separates stem cells and allows these cells to be put into storage. This process takes a few hours, and may be repeated over several days in order for doctors to get enough stem cells.

Stem cells are injected into the veins during a peripheral blood transplant, and naturally work their way to the bone marrow. Once there, the new cells start increasing healthy blood count. Compared to bone marrow transplants, cells from peripheral blood are usually faster, creating new blood cells within two weeks.

Umbilical cord blood contains a large amount of stem cells. If parents sign up for personalized storage or donation, medical staff will remove stem cells from the umbilical cord and placenta. The blood is then cryogenically frozen, and put into long-term storage.

While the stem cell count is smaller during a cord blood transplant, these cells multiply quickly, and researchers are studying new methods to increase cells naturally. Compared to bone marrow, cord blood cells multiply faster and dont require an exact match type to complete a successful transplant. Some techniques medical experts are testing to increase the amount of stem cells include:

While all three stem cell sources are used in similar procedures, they each have advantages and drawbacks. Bone marrow transplants are the traditional form of therapy, but peripheral blood cells are becoming more popular, since doctors often get more stem cells from the bloodstream.

The procedure for peripheral blood harvesting is easier on the patient than a bone marrow transplant, and stem cell transplants are faster. However, the chances for graft-versus-host disease, where donated cells attack the patients body, are much higher after a peripheral blood transplant.

Cord blood transplants are the least invasive, since they come from an external source the umbilical cord.

The biggest advantage for cord blood is the immaturity of the cells, which means transplants do not require an exact match. For bone marrow and peripheral blood transplants, donors need to match the patients cellular structure. However, cord blood cells can adapt to a wide variety of patients, and dont require donor matching. Chances for graft-versus-host disease are also much lower for cord blood transplants.

Patients and doctors can avoid graft-versus-host disease, and other dangerous side effects, by using HLA matching.

Multipotent stem cells develop into organ system cells, and are made from two different types of cells:

HSCs can become any type of blood cell or cellular blood component inside the body, including white blood cells and red blood cells. These cells are found in umbilical cord blood and are multipotent, which means they can develop into more than one cell type.

This cell type has been used in over 1 million patient transplants around the world.

MSCs can turn into bone, cartilage, fat tissue, and more. Although they are associated with bone marrow, these cells are also found in umbilical cord blood. These cells can function as connective tissue, which connects vital organs inside the body. Like HSCs, MSCs are multipotent.

Pluripotent cells can replace any type of cellular system in the body. Cord blood contains a rich variety of pluripotent stem cells, which allows treatment for a large amount of patients.

iPS cells are artificially-made pluripotent stem cells. This technique allows medical staff to create additional pluripotent cells, which will increase treatment options for patients using stem cell therapy in the near future.

ES cells are pluripotent, and similar to iPS cells, but come from an embryo. However, this kills the fertilized baby inside the embryo. This type of cell also has a high chance for graft-versus-host disease, when transplanted cells attack the patients body.

Your adult cells have one disadvantage to cord blood cells they cannot change their cell type. When stem cells from cord blood and tissue are transplanted, they adjust to fit the individual patient and replace damaged cells. Adult stem cells are also older, which means they have been exposed to disease, and may damage patients after the transplant. Compared to cord blood cells, adult cells have a higher chance for graft-versus-host disease.

Cord blood contains a wide variety of cell types, but there are different stem cell sources available to patients in need of a transplant.

Last Updated on February 15th, 2017

Original post:
Stem Cells Used in Cord Blood Treatments

One of the bravest moves in that direction has come from stem cell research and therapy. Stem cell therapy is currently being used to successfully treat more than 80 diseases, but the field is rapidly evolving backed by prestigious research and clinical trials.

Smart Cells is the first private UK stem cell storage company to have released stored stem cell units for use in the treatment of children with life-threatening illnesses. We have released the greatest number of samples for use in transplants from the UK.

We believe with the development of technology in the future we will be able to treat even more illnesses.

We believe our customers deserve the best service available and we run our state of the art facility with leading professionals in the field.

We believe that storing your childs stem cells at birth can be a crucial part of treating or curing an unexpected illness.

We believe that in the future this service should be available to every parent, child and family.

We are a company that is for life.

View post:
Storing Stem Cells For Life - Smart Cells

- 183 records -

Original Research

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Caldern-Ospina CA, Pea N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

Original Research

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Original Research

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

Review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Original Research

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

Original Research

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Original Research

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Review

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Here is the original post:
Pharmacogenomics and Personalized Medicine - Dove Press

Dennis M. Lox, M.D. Knee Stem Cell Treatments have been seen Across The Nation.

Dennis M Lox, M.D. is an expert in Knee Stem Cell Injections for those who seek an alternative to the unnecessary complex knee surgery of that in the past by providing Knee Stem Cell Treatment. Dennis M. Lox, M.D. has privately owned Medical Centers that do not partake in the fast chain franchise that other Stem Cell Centers are stuck doing, thus he is able provide a more personalized treatment for your particular injury.

Dennis M. Lox, M.D. centers have a professional, caring environment for patients looking for comfort in their time of need and provids follow-ups on your wellbeing to enhance your recovery. Dennis M. Lox, M.D. has been helping patients since 1990 nationally and internationally and has been the focus of the Stem Cell News Worldwide with his expertise and he continually researches new technologies to further Stem Cell advancements.

PUBLICATIONS:

Lox, D.M., Heine, M.W., and Lox, C.D., Hemostatic Alterations Resulting from Chronic Ethanol Ingestion during Tetracycline Therapy in the Rat, Neurobeh, Toxiocol: Vol. 7, 1985.

Lox, C.D. and Lox, D.M., Effects of Acute Ethanol Intoxication Combined with Secobarbitol Abuse on Homeostasis, General Pharm Vol. 16, 1985. 252-258.

PRESENTATIONS:

Lox, D.M., Sports Medicine and Stem Cells: A Clinical Transformation Presentation at the Select Biosciences Conference: Tissue Engineering and Bio printing, Boston, Massachusetts, February 2015

Lox, D.M., Clinical Regulation of Cytokine and Inflammatory Pathways with Autologous Stem Cell Therapy Presentation at the 17th Clinical Applications for Age Management Medicine Group, The Bellagio Hotel, Las Vegas, Nevada, October 2014

Lox, D.M., Moderator 3rd Annual International Conference on Tissue Science and Regeneration, Valencia, Spain, September 2014

Lox, D.M., Athletes and Avascular Necrosis Presentation at the 3rd Annual International Conference on Tissue Science and Regeneration, Valencia, Spain, September 2014Lox, D.M., Managing Sports and Arthritic Complaints with Stem Cells, Presentation at the Select Biosciences Clinical Translation of Stem Cells, Palm Desert, California, April 2014

Lox, D.M., A Professional Football Player with Failed Knee Surgery: A Case of Treatment with Adipose Derived Stem Cells, Presentation at the Tissue Engineering and Regenerative Medicine International Society Asia Chapter (Termis AP) Annual Conference, Shanghai, China, Oct. 2013

Lox, D.M., Chronic Foot Pain in a Ballerina: Treatment with Regenerative Medicine Presentation at the Tissue Engineering and Regenerative Medicine International Society Asia Pacific Chapter (Termis AP) Annual Conference, Shanghai, China, October 2013

Lox, D.M., Knee Osteoarthritis: Quality of Life (Q o L) Measures Following Autologous Stem Cell Therapy Presentation at the International Cartilage Repair Society Annual Meeting, Izmir, Turkey, September 2013

Lox, D.M., Cytokine Modulation with Nutraceuticals as a Synergistic Mechanism for Regenerative Grafting in Osteoarthritis Repair Presentation at the Tissue Engineering and Regenerative Medicine International Society Meeting, Istanbul, Turkey, June 2013

Lox, D.M., Arthritis: Quality of Life (Q o L) Measures following Mesenchymal Stem Cell Therapy Presentation at the Tissue Engineering and Regenerative Medicine International Society Meeting, Istanbul, Turkey, June 2013

Lox, D.M., Can Healthcare Outcomes Be Quantified with Stem Cell Therapy in Osteoarthritis?

Presentation at the World Stem Cell Summit, West Palm Beach, Fl. December 2012

Lox, D.M., Regenerative Rehabilitation of an Elite Soccer Player, Presentation at the First Annual Symposium on Regenerative Rehabilitation, Pittsburgh, PA, November 3-4, 2011.

Lox, D.M., Regenerative Medicine and Tissue Engineering: Ethical Concerns with Health Care Reform, Presentation at the 2011 World Stem Cell Summit, Pasadena, CA on October 2011.

Lox, D.M., Autologous Adipose-Derived Stem Cells in the Rehabilitation of a Soccer Player, Presentation at the Stem Cells Europe 2011 Conference, Edinburgh, Scotland on July 2011.

Lox, D.M., Autologous Human Adipose-Derived Mesenchymal Stem Cells in Orthopedic Medicine: A Veterinary Correlate, Presentation at the 2nd North American Veterinary Regenerative Medicine Conference, Lexington, Kentucky on June 2011.

Lox, D.M., Regenerative Medicine Techniques in Musculoskeletal Medicine, Presented at the

11th Annual Conference of the International Neural Transplantation and Repair, Sand Key, FL on May 2011.

Lox, D.M., Current Regenerative Medicine Techniques, Tampa, Florida on July 10, 2010.

Lox, D.M., Complex Regional Pain Syndrome Course Presentation, American Academy of Physical Medicine and Rehabilitation Annual Assembly (Moderator: Dennis M. Lox, M.D. Speakers: Jose Ochoa, M.D., Gabor Racz, M.D., Dennis M. Lox, M.D.); Seattle, Washington on November 5, 1998.

Lox, D.M., New Treatments in Myofascial Pain and Fibromyalgia, Presented at the Morton Plant/Mease Health Education Center Countryside, Florida on December 13, 2001.

Lox, D.M., Acute Spinal and Pain Syndromes Presented to the Pinellas County Primary Care and OB/GYN physicians, sponsored by Knoll Pharmaceuticals, 1998.

Lox, D.M., Complex Musculoskeletal Assessment and Treatment, Presented to the Zenith Insurance Company; Sarasota, Florida on September 28, 1998.

Lox, D.M., Fibromyalgia, Presented to Cigna Health Care Physicians, sponsored by Health South Rehabilitation Corporation; Tampa, Florida on September 19, 1998.

Lox, D.M., Evaluation of the Difficult Pain Patient, Presented to the Pinellas County Orthopedic Journal Club, sponsored by Knoll Pharmaceuticals; Clearwater, Florida on September 8, 1998.

Lox, D.M., Fibromyalgia, Presented to the Travelers Insurance Company, sponsored by Health South Rehabilitation Corporation; Tampa, Florida on August 19, 1998.

Lox, D.M., Complex Pain Management, Presented to the Physicians of Collier County, sponsored by Knoll Pharmaceuticals; Naples, Florida on May 16, 1998.

Lox, D.M., Managing Pain in a Managed Care, Presented to the Pinellas County Podiatric Medical Association Meeting; Clearwater, Florida on April 14, 1998.

Lox, D.M., Complex Regional Pain Syndrome: The Historical Perspective from Bonica and Beyond, Presented at the 7th Annual John J. Bonica Vail Winter Pain Conference, sponsored by the Ohio State University Medical Center, College of Medicine, Department of Anesthesiology; Vail, Colorado on March 1998.

Lox, D.M., Pain Management, Presented to Lee County Physicians, sponsored by Knoll Pharmaceuticals; Ft. Myers, Florida in December 1998.

Lox, D.M., Managing Pain in a Managed Care Environment, Presented to the Pinellas County Physicians, sponsored by Knoll pharmaceuticals; Clearwater, Florida in December 1997.

Lox, D.M., Regional Pain Syndrome Update, Presented at the 74th Annual Meeting of the American Congress of Rehabilitation Medicine Pain ISIG; Boston, Massachusetts in September 1997.

Lox, D.M., Physical Medicine for Women Who Hurt all Over (Physical and Somatization Considerations, and Complex Regional Pain Syndrome Update, Presented at the 9th Annual OB/GYN Summer Symposium, Womens Health Care in the 90s, sponsored by the University of Oklahoma Health Sciences Center College of Medicine, Department of Obstetrics and Gynecology; Jackson Hole, Wyoming in August 1997.

Lox, D.M., Replacing the Terms of Reflex Sympathetic Dystrophy and Sympathetically Maintained Pain-An Uphill Battle, Presented at the 13th Annual Update in Physical Medicine and Rehabilitation, sponsored by the University of Utah School of Medicine, Division of Physical Medicine and Rehabilitation, Park City, Utah, March 1997.

Lox, D.M., Complex Regional Pain Syndrome, Presented to Claim Management, Utilization Management, Case Managers, Adjustors and Supervisors of the Travelers/Aetna Insurance Companies; Orlando, Florida in August 1996.

Lox, D.M., Soft Tissue Injuries/RSD/Fibromyalgia-The Rational or Irrational Approach to Diagnosis and Treatment, Presented to Claim Management, Utilization Management, Case Managers and Supervisors of Travelers Insurance Company; Tampa, Florida, 1996.

Lox, D.M., Overview of the Soft Tissue Injury/RSD/Fibromyalgia-The Rational or Irrational Approach to Diagnosis and Treatment, Presented to the Regional Adjustors and Personnel of Geico Insurance Company; Macon, Georgia in May 1996.

Lox, D.M., Causalgia/RSD/SMP-History and Treatment, Presented during the Re-Employment rules of Florida Workers= Compensation Conference, sponsored by the Southwest Chapter of NARPPS in May 1996 (2 CME credits).

Lox, D.M., RSD-Treatment Options for the 90s, Presented to the Florida Association of Rehabilitation Professionals in the Private Sector (FARPPS) in March 1996 (2 CME credits).

Lox, D.M., Causalgia/RSD/SMP-The 100 Year War, Presented to The Florida Association of Rehabilitation Professionals in the Private Sector in January 1996 (2 CME credits)

Lox, D.M., The Differential Diagnosis of Spinal Injuries, Presented to the Intracorp Rehabilitation Nurses in April 1992 (4 CME credits).

Lox, D.M., A Physiatrist Approach to Industrial Industries, Presented to the Florida Rehabilitation Nurses in May 1991 (4 CME credits).

Lox, D.M., Skiing Injuries: Prevention and Rehabilitation, Presented at the North American Medical and Dental Association Seminar; Vail, Colorado in February 1989.

Lox, D.M., The Failed Back Patient, Presented at the Annual Texas Physical Medicine and Rehabilitation Society Meeting; Austin, Texas in August 1989.

Lox, D.M., Dermatomal Somatosensory Evoked Potentials and Gadolinium-MRI in the Evaluation of Chronic Low Back Pain, Presented at the 50th Annual Session of the American Academy of Physical Medicine and Rehabilitation; San Antonio, Texas in November 1989.

Lox, D.M., The Evaluation and Treatment of Lumbar Spine Disorders, Presented at the University of Texas Health Science Center at San Antonio, Department of Allied Health; San Antonio, Texas in December 1988.

Originally posted here:
Our Doctors - Knee Stem Cells

DUBLIN--(BUSINESS WIRE)--The "Global Personalized Medicine in Oncology Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the world's leading companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Chapters

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2014. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report Scope

This report is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

The report includes:

In this report, the available contracts are listed by:

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

For more information about this report visit https://www.researchandmarkets.com/research/jhhqcn/personalized?w=4

Read more here:
Personalized Medicine in Oncology: Global Partnering Terms ...

While some researchers still claim that embryonic stem cells (ESCs) offer the best hope for treating many debilitating diseases, there is now a great deal of evidence contrary to that theory. Use of stem cells obtained by destroying human embryos is not only unethical but presents many practical obstacles as well.

"Major roadblocks remain before human embryonic stem cells could be transplanted into humans to cure diseases or replace injured body parts, a research pioneer said Thursday night. University of Wisconsin scientist James Thomson said obstacles include learning how to grow the cells into all types of organs and tissue and then making sure cancer and other defects are not introduced during the transplantation. 'I don't want to sound too pessimistic because this is all doable, but it's going to be very hard,' Thomson told the Wisconsin Newspaper Association's annual convention at the Kalahari Resort in this Wisconsin Dells town. 'Ultimately, those transplation therapies should work but it's likely to take a long time.'....Thomson cautioned such breakthroughs are likely decades away."

-Associated Press reporter Ryan J. Foley "Stem cell pioneer warns of roadblocks before cures," San Jose Mercury News Online, posted on Feb. 8, 2007, http://www.mercurynews.com/mld/mercurynews/16656570.htm

***

"Although embryonic stem cells have the broadest differentiation potential, their use for cellular therapeutics is excluded for several reasons: the uncontrollable development of teratomas in a syngeneic transplantation model, imprinting-related developmental abnormalities, and ethical issues."

-Gesine Kgler et al., "A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential," Journal of Experimental Medicine, Vol. 200, No. 2 (July 19, 2004), p. 123.

***

From a major foundation promoting research in pancreatic islet cells and other avenues for curing juvenile diabetes:

"Is the use of embryonic stem cells close to being used to provide a supply of islet cells for transplantation into humans?

"No. The field of embryonic stem cells faces enormous hurtles to overcome before these cells can be used in humans. The two key challenges to overcome are making the stem cells differentiate into specific viable cells consistently, and controlling against unchecked cell division once transplanted. Solid data of stable, functioning islet cells from embryonic stems cells in animals has not been seen."

-"Q & A," Autoimmune Disease Research Foundation, http://www.cureautoimmunity.org/Q%20&%20A.htm, accessed July 2004.

***

"'I think the chance of doing repairs to Alzheimer's brains by putting in stem cells is small,' said stem cell researcher Michael Shelanski, co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at the Columbia University Medical Center in New York, echoing many other experts. 'I personally think we're going to get other therapies for Alzheimer's a lot sooner.'...

"[G]iven the lack of any serious suggestion that stem cells themselves have practical potential to treat Alzheimer's, the Reagan-inspired tidal wave of enthusiasm stands as an example of how easily a modest line of scientific inquiry can grow in the public mind to mythological proportions.

"It is a distortion that some admit is not being aggressively corrected by scientists.

"'To start with, people need a fairy tale,' said Ronald D.G. McKay, a stem cell researcher at the National Institute of Neurological Disorders and Stroke. 'Maybe that's unfair, but they need a story line that's relatively simple to understand.'"

-Rick Weiss, "Stem Cells an Unlikely Therapy for Alzheimer's," Washington Post, June 10, 2004, p. A3.

***

"ES [embryonic stem] cells and their derivatives carry the same likelihood of immune rejection as a transplanted organ because, like all cells, they carry the surface proteins, or antigens, by which the immune system recognizes invaders. Hundreds of combinations of different types of antigens are possible, meaning that hundreds of thousands of ES cell lines might be needed to establish a bank of cells with immune matches for most potential patients. Creating that many lines could require millions of discarded embryos from IVF clinics."

-R. Lanza and N. Rosenthal, "The Stem Cell Challenge," Scientific American, June 2004, pp. 92-99 at p. 94. [Editor's note: A recent study found that only 11,000 frozen embryos are available for research use from all the fertility clinics in the U.S., and that destroying all these embryos for their stem cells might produce a total of 275 cell lines. See Fertility and Sterility, May 2003, pp. 1063-9 at p. 1068.]

***

"Embryonic stem cells have too many limitations, including immune rejection and the potential to form tumors, to ever achieve acceptance in our lifetime. By that time, umbilical cord blood stem cells will have been shown to be a true 'gift from the gods.'"

-Dr. Roger Markwald, Professor and Chair of Cell Biology and Anatomy at the Medical University of South Carolina, quoted in "CureSource Issues Statement on Umbilical Cord Blood Stem Cells vs. Embryonic Stem Cells," BusinessWire, May 12, 2004, also at http://curesource.net/why.html.

***

"'We're not against stem-cell research of any kind,' said [Tulane University research professor Brian] Butcher. 'But we think there are advantages to using adult stem cells. For example, with embryonic stem cells, a significant number become cancer cells, so the cure could be worse than the disease. And they can be very difficult to grow, while adult stem cells are easy to grow.'"

-Heather Heilman, "Great Transformations," The Tulanian (Spring 2004 issue), at http://www2.tulane.edu/article_news_details.cfm?ArticleID=5155.

***

"There are still many hurdles to clear before embryonic stem cells can be used therapeutically. For example, because undifferentiated embryonic stem cells can form tumors after transplantation in histocompatible animals, it is important to determine an appropriate state of differentiation before transplantation. Differentiation protocols for many cell types have yet to be established. Targeting the differentiated cells to the appropriate organ and the appropriate part of the organ is also a challenge."

-E. Phimister and J. Drazen, "Two Fillips for Human Embryonic Stem Cells," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1351-2 at 1351.

***

Harvard researchers, trying to create human embryonic stem cell lines that are more clinically useful than those now available, find that their new cell lines are already genetically abnormal:

"After prolonged culture, we observed karyotypic changes involving trisomy of chromosome 12..., as well as other changes... These karyotypic abnormalities are accompanied by a proliferative advantage and a noticeable shortening in the population doubling time. Chromosomal abnormalities are commonplace in human embryonal carcinoma cell lines and in mouse embryonic stem-cell lines and have recently been reported in human embryonic stem-cell lines."

-C. Cowan et al., "Derivation of Embryonic Stem-Cell Lines from Human Blastocysts," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1353-6 at 1355.

***

"[Johns Hopkins University] biologist Michael Shamblott said...major scientific hurdles await anybody wishing to offer a treatment, let alone a cure, based on cells culled from embryos.

"Among the major obstacles is the difficulty of getting embryonic stem cells master cells that generate every tissue in the human body to become exactly the type of cell one wants... Scientists...haven't been able to guarantee purity cells, for instance, that are destined to become muscle cells and nothing else...

"Transplanting a mixed population of cells could cause the growth of unwanted tissues. The worst case could see stem cells morphing into teratomas, particularly gruesome tumors that can contain hair, teeth and other body parts.

"Another issue is timing... Stem cells pass through many intermediate stages before they become intermediate cells such as motor neurons or pancreatic or heart cells. Deciding when to transplant remains an open question, and the answer might differ from disease to disease.

"...In tackling Lou Gehrig's disease, [Johns Hopkins neurologist Dr. Jeffrey] Rothstein figured that cells that haven't committed themselves to becoming motor neurons would stand the best chance, once implanted, of reaching out and connecting with the cells that surround them. What he found, however, is that these immature cells didn't develop much once transplanted into lab animals."

-Jonathan Bor, "Stem Cells: A long road ahead," Baltimore Sun, March 8, 2004, p. 12A.

***

"Tony Blau, a stem-cell researcher at the University of Washington, said it is 'extremely laborious' to keep embryonic cells growing, well-nourished and stable in the lab so they don't die or turn into a cell type with less potential. Researchers need to know how to channel the stem cells to create a specific kind of cell, how to test whether they're pure, and how to develop drugs that could serve as a sort of antidote in case infused stem cells started creating something dangerous, such as cancer.

"Big companies, Blau said, want to know that their drugs will be almost completely stable, standard, pure and consistent, because they can behave differently if they aren't. Stem cells never will achieve that kind of standardization, Blau said, because living cells are more complex than chemically synthesized drugs."

-Luke Timmerman, "Stem-cell research still an embryonic business," Seattle Times, Business & Technology section, February 22, 2004, at http://seattletimes.nwsource.com/html/businesstechnology/2001862747_stemcells22.html.

***

"[W]ithin the ESC research community, realism has overtaken early euphoria as scientists realize the difficulty of harnessing ESCs safely and effectively for clinical applications. After earlier papers in 2000 and 2001 identified some possibilities, research continued to highlight the tasks that lie ahead in steering cell differentiation and avoiding side effects, such as immune rejection and tumorigenesis."

-Philip Hunter, "Differentiating Hope from Embryonic Stem Cells," The Scientist, Vol. 17, Issue 34 (December 15, 2003), at http://www.the-scientist.com/yr2003/dec/hot_031215.html.

***

"Long-term culture of mouse ES [embryonic stem] cells can lead to a decrease in pluripotency and the gain of distinct chromosomal abnormalities. Here we show that similar chromosomal changes, which resemble those observed in hEC [human embryonal carcinoma] cells from testicular cancer, can occur in hES [human embryonic stem] cells.... The occurrence and potential detrimental effects of such karyotopic changes will need to be considered in the development of hES cell-based transplantation therapies."

-J. Draper et al., "Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells," Nature Biotechnology, Vol. 22 (2003), pp. 53-4.

***

"James A. Thompson of the University of Wisconsin, Madison, and his colleagues managed to isolate and culture the first human embryonic stem cells in 1997. Five years later, big scientific questions remain. [Harvard embryonic stem cell researcher Doug] Melton and his colleagues, for instance, don't yet know how to instruct the totipotent stem cells to become the specific cells missing in a diabetic person, the pancreatic beta cell.

"'Normally, if you take an embryonic stem cell, it will make all kinds of things, sort of willy-nilly,' says Melton."

-J. Mitchell, "Stem Cells 101," PBS Scientific American Frontiers, May 28, 2002, http://www.pbs.org/saf/1209/features/stemcell.htm.

***

"Unlike stem cells isolated from the embryo, [adult stem cells] do not carry the same risks of cancer or uncontrollable growth after transplant, and they can be isolated from patients requiring treatment, thus avoiding all problems of immune rejection and the need for immune suppressive drugs that carry their own risks.

"...Embryonic stem cells are promoted on grounds that they are developmentally more flexible than adult stem cells. But too much flexibility may not be desirable. Transplant of embryonic cells into the brains of Parkinson's patients turned into an irredeemable nightmare because the cells grew uncontrollably. Embryonic stem cells also show genetic instability and carry considerable risks of cancer... When injected under the skin of certain mice, they grow into teratomas, tumors consisting of a jumble of tissue types, from gut to skin to teeth, and the same happens when injected into the brain."

-Dr. Mae-Wan Ho and Prof. Joe Cummins on behalf of the Institute of Science in Society (ISIS), "Hushing Up Adult Stem Cells," ISIS report, February 11, 2002, at http://www.i-sis.org.uk/HUASC.php.

***

"'I even hear from patients whose fathers have lung cancer,' said Dr. Hogan, a professor at Vanderbilt School of Medicine. 'They have a whole slew of problems they think can be treated. They think stem cells are going to cure their loved ones of everything.'

"If it ever happens, it will not happen soon, scientists say. In fact, although they worked with mouse embryonic stem cells for 20 years and made some progress, researchers have not used these cells to cure a single mouse of a disease...

"Scientists say the theory behind stem cells is correct: the cells, in principle, can become any specialized cell of the body. But between theory and therapy lie a host of research obstacles...the obstacles are so serious that scientists say they foresee years, if not decades, of concerted work on basic science before they can even think of trying to treat a patient."

-Gina Kolata, "A Thick Line Between Theory and Therapy, as Shown with Mice," New York Times, December 18, 2001, p. F3.

***

"Mice cloned from embryonic stem cells may look identical, but many of them actually differ from one another by harboring unique genetic abnormalities, scientists have learned...

"The work also shows for the first time that embryonic stem cells...are surprisingly genetically unstable, at least in mice. If the same is true for human embryonic stem cells, researchers said, then scientists may face unexpected challenges as they try to turn the controversial cells into treatments for various degenerative conditions."

-Rick Weiss, "Clone Study Casts Doubt on Stem Cells," Washington Post, July 6, 2001, p. A1.

***

"ES cells have plenty of limitations... For one, murine ES cells have a disturbing ability to form tumors, and researchers aren't yet sure how to counteract that. And so far reports of pure cell populations derived from either human or mouse ES cells are few and far between fewer than those from adult stem cells."

-Gretchen Vogel, "Can Adult Stem Cells Suffice?", Science, Vol. 292 (June 8, 2001), pp. 1820-1822 at 1822.

***

"Rarely have specific growth factors or culture conditions led to establishment of cultures containing a single cell type.... [T]he possibility arises that transplantation of differentiated human ES cell derivatives into human recipients may result in the formation of ES cell-derived tumors... Irrespective of the persistence of stem cells, the possibility for malignant transformation of the derivatives will also need to be addressed."

-J. S. Odorico et al, "Multilineage differentiation from human embryonic stem cell lines," Stem Cells Vol. 19 (2001), pp. 193-204 at 198 and 200, at http://stemcells.alphamedpress.org/cgi/reprint/19/3/193.pdf.

Originally posted here:
Practical Problems with Embryonic Stem Cells - usccb.org

The mission of the Seed Biotechnology Center (SBC)is to mobilize the research, educational and outreach resources of UC Davis in partnership with the seed and biotechnology industries to facilitate discovery and commercialization of new seed technologies for agricultural and consumer benefit.

A team of researchers including SBC Director of Research, Dr. Allen Van Deynze and Cristobal Heitmann, discover an indigenous variety of corn that can fix nitrogen from the atmosphere, instead of requiring synthetic fertilizers. Cristobal Heitman, Cris, was a beloved member of the UC Davis Plant Sciences Department. Criss energy and enthusiasm were a major catalyst in this research. Read more.

Plant Breeding Academy Addresses Global Food Needs

UC Davis' Department of Plant Sciences shares how PBA is changing the global food supply one scientist at a time.Read article.

A DryCardis the latest technology to improve the shelf-life of seeds. Dr. Kent Bradford, SBCDirector, describes how the amazingDryCard works. Read more.

Comstock Magazine highlighted the value of locating Sakatas Woodland Innovation Center in the Sacramento Valley. The regions fertile soil and ideal climate make it one of the best places in the world for seed production. In addition, its close proximity to UC Davis will allow Sakata to strengthen its already existing ties to the university. Learn more.

Scientists could engineer a spicy tomato. Is it worth it?

Scientists are working on growing a spicy tomato. Dr. Allen Van Deyneze, SBC Director of Research shares his insight on the research. Read article.

Benson Hill Teams Up with The African Orphan Crops Consortium to Combat Malnutrition Through Underutilized Crops

Allen Van Deynze, Director of Research, Seed Biotechnology Center, University of California, Davis and Scientific Director of the African Orphan Crops Consortium highlights effort to accelerate the ability of African scientists to develop better seeds and improve the diets of Africas children. Learn more

See the rest here:
Welcome to the SBC - Seed Biotechnology Center

According to U. S. records, the number of individuals over 100 years of age known as Centenarians is skyrocketing! In the US in 1840 there were 90 centenarians which is 1 for every 189,000 people. Today there are more than 53,000 which is 1 for every 5,800 people. To find out why some people live so long, the world was searched for places where there are an unusually large number of centenarians. Those places became known as Blue Zones based on a National Geographic book that was published a few years ago.

There were four areas of the world known as Blue Zones in the original book with a fifth more recently addedOkinawa, Japan; Ikaris, Greece; Loma Linda, California; Nicoya, Costa Rico; and Sardinia, Italy. Experts cite that an active lifestyle and a healthy diet as the keys to a longer life. In Blue Zones people are passionate about retaining close family ties and staying closely connected to their neighbors and community organizations.

Okinawa has the highest number of centenarians in the world. Two thirds of the people who reach 100 in this country are able to continue living independently at age 97. These people are three times more likely to reach the age of 100 than maost Americans. Additionally, they have very low rates of stroke, cancer, heart disease and diabetes. Researchers are convinced that their diet is the key component to their longevity.

The diet of Okinawan is high in vegetables and fruits, high in plant proteins, includes seafood and is also rich in whole grains. Scientists from the Eat Lancet Commission say this diet closely resembles their planetary health diet which is a diet that works well for human health and also for reducing the environmental impact of the foods we choose.

Some of the most widely consumed foods in Okinawa include green leafy and yellow root vegetables, sweet potatoes, bitter melon, tofu with modest amount of seafood, lean meat, tea and fruit. This diet is low calorie and high carbohydrate with moderate protein consumption, includes nutrient rich food choices and sparse amounts of refined grains sugar, dairy and meat. A typical meal will include a vegetable stir fry, miso soup, a side of seaweed and freshly brewed jasmine tea.

In addition to a healthy diet, Okinawans maintain close social ties and networks with a grounded sense of purpose. These people remain true to their traditional culture which emphasizes lifelong connections with social and emotional support.

Another Blue Zone is Ikaris, Greece. The residents in this part of the world nap regularly in the middle of the day. None of them exhibit symptoms of depression which non nappers do according to a 2011 study. One study of Greek adults showed that napping on a regular basis reduced the risk of heart disease by close to 40%.

These people of Greece follow a Mediterranean diet which includes natural products produced and consumed on the island of Ikaris. Their diet includes fruits, a variety of vegetables, olive oil, fish, honey, red wine, small quantities of coffee and a variety of herbal teas. Their daily calorie consumption is not high. They have minimal drug use, live a relaxed pace without anxiety and stress, are full of optimism and have strong family and social ties. All characteristics that are abundant in all five Blue Zones!

In Loma Linda, California the proportion of people age 85 or more is more than double the rest of this state. 4 in 10 residents of this city (about 9,000 members) are 7th Day Adventists whose members live longer than any other religious group in America. 7th Day Adventists are 10 times more likely to live to 100 than other Americans. The average male lives to 89 while the average female lives to 91. Both are averages of 10 years longer than the American average. This group of people believe in taking care of their bodies which they do through exercise, healthy diet habits and their close ties to their religious community.

They avoid smoking and alcohol while encouraging exercise and a life full of activity. Their diet typically includes nuts, green salads, fruits, legumes, whole grain cereals and polyunsaturated fats. Many are vegetarians and those who are not eat a low meat diet. They avoid foods high in sugar, salt and stay away from refined grains.

The next Blue Zone is Nicoya, Costa Rica which is known as one of the happiest places in the world! In this area of the world a man at the age of 60 is twice more likely of hitting 90 as a man living in America, France or Japan and residents frequently reach the age of 100. Once again, their long lives are attributed to their healthy lifestyle.

Their largest meal of the day is typically in the morning with their smallest meal of the day at night. They eat little or no processed foods and their diet is primarily plant based. They consume large amounts of beans, vegetables, corn and antioxidant rich tropical fruits. The consume meat only a few times a week and smoking is not common. They also drink a lot of mineral rich water which is very high in calcium and magnesium and get very healthy doses of sunshine on a daily basis.

These people also have a very strong belief in God, and their faith routines help them relieve anxiety and stress and bring tranquility and peace to their lives. They engage in physical activity as a normal part of their daily liveswalking, bicycling, cooking, keeping up their houses, gardening and taking care of animals are all parts of their very active lives.

These residents of Coats Rice focus on family by tending to live with or near their families. Children and grandchildren provide strong support, purpose and a sense of belonging to their elders. This helps Nicoyan elders retain their active lifestyle and positive outlook on life!

Sardinia, Italy is the fifth Blue Zone. There are 21 centenarians in a population of 10,000. In the U. S. there only about 4 centenarians in 10,000. Here Sardinia men live longer than any other men on earth.

There is a large number of sheep herding and farming communities where daily physical activity is strong. Many of these residents walk up to 5 miles a day across rugged terrain. They tend to walk daily to the grocery store. Many Sardinians still fish, hunt and harvest their own food. And even though they are culturally isolated, they remain close to friends and family throughout their lives. They like to laugh and drink wine together!

Their diet like the other Blue Zones is comprised of homegrown vegetables and fruits, beans, fish and milk and cheese from grass fed sheep and goats. Goats milk has components that are thought to protect against inflammatory diseases of aging. And they like their wine! They typically drink a glass or two daily of red wine. Cannonau wine which is the wine produced in this area from the grape known as Grenache, has three times the levels of artery scrubbing flavonoids as other wines.

These people laugh with friends. They gather each afternoon in the street to talk and laugh and the men of this region are famous for their sardonic sense of humor. And their strong sense and support of family keeps the young looking after their elders with many believing that putting an older family member in a retirement home would dishonor the family!

For Americans and others, following the habits of the people living in the five Blue Zones may help improve daily health and longevity. Taking notes about diet, daily exercise and activity; close ties to family, friends and community; purpose; and a positive outlook and gratitude on life are key. It is known that all these factors play a role in aging and age related diseases.

Read the original post:
Anti-Aging, Regeneration and Stem Cell Supplements

center for biomedical education

The mission of the Center for Biomedical Education encompasses education in the basic medical and clinical sciences and educational research related to the training of medical doctors. CBE undertakes and fosters conferences, meetings, workshops, and publications by and for medical educators. Activities further the purposes of ICSM by promoting effective training of medical doctors and thereby conferring a benefit to society.

IIHER is a nonprofit research organization with origins dating back to 1991 whose purpose it is to investigate human evolutionary biology using the widest possible purview. IIHER serves as the basis for paleoanthropological research expeditions, primarily to Africa. Active now is the East Libya Neogene Research Project to the late Miocene site of Sahabi and the middle Miocene site of Jabal Zaltan, Libya.

The primary activity of CFSHR is the forensic scientific investigation of primarily skeletonized human remains worldwide, particularly those found in circumstances indicating abuses of human rights, such as mass graves, ethnic cleansing, torture, or genocide. A secondary activity is forensic assistance lent to medical examiners offices and regional law enforcement agencies primarily in Oregon, California, and Washington in solving missing person and homicide cases.

More:
Integrative Centers for Science and Medicine - Home

The procedure lasts about 3040 minutes, using local anesthetic with very little discomfort, and after it is completed you will be able to walk out of the office and drive yourself home.

This is in contrast to prolonged hospital stays with extensive down time and expense associated with various surgical procedures, including total knee replacements. The average cost of a total knee replacement in the U.S. is $40,000, and often associated with mediocre results, especially with regard to functionality.

Stem Cell Prolotherapy offers a much better solution with potentially better results, especially mobility, at a fraction of the cost. There are other treatment modalities sometimes used to lubricate the knee joint, such as Hyaluronate, known by the brand names, Synvisc or Euflexxa.

The problem with these is that they are only a temporary solution, which at best will only last for about six months before the procedure will need to be repeated. This is in stark contrast to the permanent healing and regeneration, which is achieved with the Stem Cell Prolotherapy.

However, Hyaluronate can be used in conjunction with the Stem Cell Prolotherapy so that you can enjoy the benefits of both therapies, if you choose.

Visit link:
Stem Cell Joint Regeneration | Utah Stem Cells